Free Trial
NASDAQ:ATYR

aTyr Pharma Q1 2024 Earnings Report

aTyr Pharma logo
$5.52 +0.34 (+6.45%)
As of 02:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

aTyr Pharma EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.24
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

aTyr Pharma Revenue Results

Actual Revenue
$0.24 million
Expected Revenue
$0.11 million
Beat/Miss
Beat by +$130.00 thousand
YoY Revenue Growth
N/A

aTyr Pharma Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 2, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

aTyr Pharma's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

aTyr Pharma Earnings Headlines

aTyr Pharma Inc Executives - Morningstar
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
aTyr Pharma (ATYR) Gets a Buy from H.C. Wainwright
See More aTyr Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email.

About aTyr Pharma

aTyr Pharma (NASDAQ:ATYR) (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on the discovery and development of novel protein therapeutics that harness the body’s natural processes to treat severe diseases. Founded as a spin-out from leading academic research institutions, the company pioneers the field of extracellular modulation of intracellular targets through its proprietary XCEPTOR platform. This technology leverages engineered proteins derived from aminoacyl tRNA synthetases to regulate cellular stress responses, offering a new modality for treating inflammatory, fibrotic and immune-mediated disorders.

The company’s lead clinical candidate, ATYR1923 (resolaris), is an engineered human protein designed to bind to neuropilin-2 and modulate immune activity in the lung. ATYR1923 is being evaluated in patients with pulmonary sarcoidosis and other interstitial lung diseases, where inflammation and fibrosis can cause progressive respiratory impairment. Earlier-stage programs target indications such as pulmonary arterial hypertension and select oncology settings, illustrating aTyr’s commitment to translating its platform across therapeutic areas with high unmet medical need.

Headquartered in San Diego, California, aTyr Pharma conducts research and development operations in the United States and collaborates with academic centers and industry partners in North America and Europe. The company maintains active clinical trial sites across multiple geographies to support robust patient enrollment and regulatory engagement. Its approach combines late-stage development rigor with the agility of a focused biotech, aiming to advance candidates efficiently through clinical milestones.

aTyr is led by a seasoned management team with extensive experience in biopharmaceutical R&D, regulatory affairs and commercial strategy. The board and executive officers bring expertise from established life science companies, with a shared vision of delivering differentiated protein therapeutics. With its innovative platform and advancing clinical pipeline, aTyr Pharma seeks to offer new treatment options for patients suffering from debilitating diseases driven by inflammatory and fibrotic pathways.

View aTyr Pharma Profile

More Earnings Resources from MarketBeat